BioNTech Founders to Depart, Form New mRNA-Focused Company
Ugur Sahin and Özlem Türeci, the couple who co-founded BioNTech, are leaving the Covid-19 vaccine maker to start a new, mRNA-focused firm.
Editorial Staff Mar 10
Health
Latest Health stories from Life.
Briefing: Health AI startup to benefit from $1 billion funding round for Yann LeCun’s AMI
Strategic angle: AI scribe company Nabla aims to be much more by using tech from Yann LeCun's new startup AMI, which just raised $1 billion.
Editorial Staff Mar 10
Briefing: U.S. Senator Probes FDA Amid BioNTech Founders' Departure
Strategic angle: The co-founders of BioNTech, known for their Covid-19 vaccine, are set to leave the company to launch a new mRNA-focused venture.
Editorial Staff Mar 10
Briefing: Amid dueling autism meetings, HHS cancels
Strategic angle: Epilepsy med response, a long-awaited fix to the kidney transplant system, and more health news
Editorial Staff Mar 10
Briefing: Oral Contraceptive Pills: Access and Availability
Strategic angle: An overview of oral contraception, insurance coverage, and strategies to enhance access for women.
Editorial Staff Mar 10
Briefing: Large drugmakers are developing fewer antibiotics, analysis finds
Strategic angle: The number of potential antimicrobial treatments being developed by the world’s largest drugmakers nosedived by 35% over the past five years, according to a new analysis.
Editorial Staff Mar 10
Briefing: Removing race from kidney function algorithm helped more Black patients access transplants
Strategic angle: A significant change in the eGFR algorithm led to increased kidney transplant opportunities for Black patients.
Editorial Staff Mar 10
Briefing: Over-the-Counter Oral Contraceptive Pills Approved
Strategic angle: FDA approves Opill, marking a significant change in access to oral contraceptives in the U.S.
Editorial Staff Mar 10
Briefing: Vertex says its drug successfully reduced marker of kidney disease in late-stage trial
Strategic angle: Vertex reported that its drug, acquired for $4.9 billion, halved a key marker of IgA nephropathy in late-stage trials.
Editorial Staff Mar 9
Briefing: The ER Staffing Conflict and No Facility Fee for a Marmot
Strategic angle: A battle between doctors and a hospital system is an early test of a new law designed to separate business and medicine.
Editorial Staff Mar 9
Briefing: A setback for Roche’s breast cancer drug
Strategic angle: Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news
Editorial Staff Mar 9
Briefing: Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales
Strategic angle: Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug.
Editorial Staff Mar 9
Briefing: Fresh turmoil at the FDA with Prasad’s exit
Strategic angle: Prasad out again, generic Ozempic on its way, and more health news from Morning Rounds
Editorial Staff Mar 9
Briefing: Lack of FDA Advisory Committees Raises Concerns
Strategic angle: Growing worries about the FDA's diminishing use of advisory committees for public discourse.
Editorial Staff Mar 9
Briefing: Talkspace to be acquired for $835 million by mental health services giant
Strategic angle: Universal Health Services announces acquisition of virtual mental health company Talkspace.
Editorial Staff Mar 9
Briefing: Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trial
Strategic angle: Xenon Pharmaceuticals reported significant reduction in seizure frequency with its new treatment compared to placebo.
Editorial Staff Mar 9
Briefing: Blue Cross Blue Shield says data back up claim that AI is driving up medical bills
Strategic angle: A new data analysis from Blue Cross Blue Shield shows how AI coding may be driving up the cost of health care.
Editorial Staff Mar 9
Briefing: Health tech company says it will dive into Medicare’s new chronic care experiment
Strategic angle: How a remote patient monitoring company is reworking its tech to enroll in a Medicare program seeking to align payment with health care outcomes.
Editorial Staff Mar 9
Briefing: Opinion: The financial reason why parents beg me to diagnose their kids with autism
Strategic angle: Parents often pressure Lawrence Diller, a behavioral/developmental pediatrician, to diagnose their children with autism. He thinks he knows why.
Editorial Staff Mar 9
Briefing: STAT+: As controversial decisions mount, FDA shuns public advisory meetings
Strategic angle: The FDA is cutting back on public advisory committee meetings, even as the public and other stakeholders seek more transparency.
Editorial Staff Mar 9